Innocan Pharma Corporation

Recent News

  • Innocan Pharma Provides an Operational Update

    Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - September 21, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical tech company focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, is pleased to provide the following operational update on its key lines of business:Recent development: We are happy to announce that the PCT title as " CANNABIDIOL-CONTAINING COMPOSITIONS AND USES THEREOF " was entered national phase in US and...

    2022-09-21 7:05 AM EDT
  • Innocan Pharma Reports Another Successful Result from a Pre-Clinical Study on a Dog Suffering from Refractory (Drug-Resistant) Epilepsy Following LPT Treatment

    A 4-year-old intact male border collie dog with a body weight of 22 kg was suffering from refractory idiopathic (drug-resistant) epilepsyThe dog was frequently hospitalized to stop seizure clusters Following treatment using Innocan's LPT (CBD Loaded Liposome Platform), seizures stopped for 9.5 weeksHerzliya, Israel and Calgary, Alberta--(Newsfile Corp. - September 9, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce additional positive results in a new preclinical trial involving a...

    2022-09-09 3:00 AM EDT
  • Innocan Pharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022

    Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - September 6, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical tech company focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, today announced that Iris Bincovich CEO of Innocan Pharma, will participate in the H.C. Wainwright 24th Annual Global Investment Conference to be held at the Lotte New York Palace Hotel in New York City on September 12-14, 2022.Mrs. Iris Bincovich's...

    2022-09-06 3:00 AM EDT
  • Innocan Pharma Announces Q2 2022 Results with 70% Annual Increase in Cash Balance and 70% Increase in Working Capital

    Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - August 30, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to report its financial results for the quarter ended June 30, 2022. Second Quarter 2022 Financial and Operating Highlights (unaudited):Cash balance at end of Q2-22 - USD 7.7M, in Q2-21 - USD 4.6M, an increase of approximately of 70% from the corresponding quarter.Revenues in Q2-22 - USD 415 thousand compared to Q2-21 - USD...

    2022-08-30 3:00 AM EDT
  • Innocan Pharma Meets Pre-Clinical End-Point in Pilot Pain Study on Dogs Using LPT Liposome Technology

    6 dogs suffering from osteoarthritis and lameness demonstrated CBD concentrations 6 weeks after a single injectionPain and well-being scores improved following treatmentHerzliya, Israel and Calgary, Alberta--(Newsfile Corp. - August 17, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce positive partial results in a pilot pain study in dogs using the LPT CBD Liposomal Delivery Platform.Six dogs suffering from osteoarthritis and lameness that were treated with oral analgesics but were...

    2022-08-17 3:00 AM EDT
  • Innocan Pharma Is Reaching Close to 100% CBD Bioavailability In a Dog Clinical Study For its Proprietary LPT CBD Liposomal Delivery Platform

    First results from a study on dogs showed close to 100% bioavailability of CBD using Innocan's LPT technologyThis is compared to 6.5-20% bioavailability in humans when administered orallyHerzliya, Israel and Calgary, Alberta--(Newsfile Corp. - August 11, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce results that approached 100% bioavailability following subcutaneous injection of its CBD proprietary LPT delivery system in a clinical study conducted on dogs suffering from pain...

    2022-08-11 3:00 AM EDT
  • Innocan Pharma Files PCT Patent Application for Novel Composition for Preventing and Treating Hair Loss

    Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - August 5, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce that it has filed a new patent application (PCT) entitled "compositions for treatment of hair loss", claiming priority from an earlier US provisional patent application. The composition developed by Innocan research and development and disclosed in the current PCT can be used to treat and prevent hair loss and is applied topically...

    2022-08-05 3:00 AM EDT
  • Innocan Pharma Files PCT Patent Application for Diabetic Symptoms

    Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - July 29, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce that it has filed a new patent application (PCT) entitled "compositions for treatment of diabetic symptoms", claiming priority from an earlier US provisional patent application. This application contributes to Innocan's continued expansion of its health and wellness intellectual property portfolio of 14 patent families. The application will ultimately result in more comprehensive...

    2022-07-29 3:00 AM EDT